top of page
Fall 2023 HMS Banner  (1)_edited.png

Longwood Healthcare Leaders Boston CEO

BioPharma industry leaders will convene at the Mandarin Oriental Hotel Boston for an off-the-record networking and brainstorming forum focused on accelerating the translation of discoveries into medicines to help patients.

On Website_edited.png

October 28 - 29, 2024

Featured Speakers

2023 Featured Speakers

Featured Firesides

Academia

R&D Leaders

BioPharma CEOs

BD & Strategy

Longwood Portfolio

Agenda

2023 Agenda

Day 1

Day 1

7:30 am

LONGWOOD FUND INTRODUCTION

Christoph Westphal, General Partner, Longwood Fund

8:00 am

PHARMA PIPELINE SOURCING

Adam Feire¸ Global Head Search & Evaluation, Novartis

Sasha Huhalov, Head, Oncology Search and Evaluation, Takeda

Aakanksha Khandelwal, Global Commercial Lead, Oncology, Daiichi Sankyo

Tonya Villafana, Global Infection Franchise Head, Vaccines & Immune Therapies, AstraZeneca

Moderator: Anita Meiklejohn, Principal, Fish & Richardson

7:00 am

REGISTRATION & NETWORKING BREAKFAST

8:30 am

ALIGNING PRIORITIES FOR THE PARTNERSHIP

Vanessa AlmendroHead, Innovation, Danaher

Al Beardsley, COO, Galera Therapeutics

Robert Blum, CEO, Cytokinetics

Devyn Smith, CEO, Arbor Biotech

Moderator: Daniela Iwanski, VP, Executive and Board Recruiting, Govig

9:00 am

REGULATORY & INDUSTRY ROUNDTABLE

Peter Marks, Director, CBER, FDA

David Redfern, President, Corporate Development, GSK

Moderator: Christoph Westphal, General Partner, Longwood Fund

9:20 am

POLICY IMPACT ON INNOVATION

Meg Alexander, Chief Strategy and Corporate Affairs Officer, Ovid

Juliette Han, CFO & COO, Cambrian

Rachid Izzar, EVP, Head, Global Product Strategy & Commercialization, Biogen

Elizabeth Jeffords, CEO, Iolyx

Moderator: Jocelyn Ulrich, Deputy VP, Policy & Research, PhRMA

9:50 am

NETWORKING BREAK

10:20 am

INNOVATION IN CLINICAL TRIAL DESIGN

Rachel Humphrey, CEO, Normunity

Jak Knowles, CEO, Affini-T Therapeutics

Kinnari Patel, President & COO, Rocket Pharma

Amanda Wagner, CEO, Immunitas

Moderator: Zhen Su, CEO, Marengo Therapeutics

10:50 am

ENSURING HEALTH EQUITY & ACCESS

Ruxandra Draghia-Akli, Global Head, Global Public Health R&D, Janssen

Anne Klibanski, President & CEO, Mass General Brigham

Kabir Nath, CEO, Compass Pathways

Cindy Perettie, EVP, Kite Pharma

Moderator: Sheila Mikhail, Co-Founder, AskBio

11:20 am

FIRESIDE CHAT

Lew Cantley, Professor, Cell Biology, Harvard Medical School

George Daley, Dean, Harvard Medical School

Moderator: Christoph Westphal, General Partner, Longwood Fund

11:40 am

DRUG DISCOVERY SCIENCES

Laurent Audoly, CEO, Ruptakine

Chris Gibson, CEO, Recursion Pharmaceuticals

Jason Kelly, CEO, Ginkgo Bioworks

Moderator: Markus Haeberlein, SVP, Head, Research, Alkermes

12:10 pm

NETWORKING LUNCHEON

1:00 pm

R&D TRANSFORMATION

John Lepore, Head, Research, GlaxoSmithKline

John Renger, CSO, Cerevel

Kailash Swarna, Managing Director, Accenture

Tadaaki Taniguchi, CMO, Astellas

Brian Vandahl, SVP, Head, Global Research Technologies, Novo Nordisk

Moderator: Jane Wilkinson, Executive Director, Koch Institute at MIT

1:30 pm

DEAL MAKING FORECAST

Jennifer CayerCBO, Pulmocide

Thaminda Ramanayake, CBO, Affini-T Therapeutics

Beth ShaferCBO, Voyager Therapeutics

Lynne Sullivan, CFO & Head, Corporate Development, Unity Biotechnology

Moderator: Bob Silverman, CBO, Turbine

2:00 pm

RARE DISEASE INNOVATION

PJ Brooks, Deputy Director, Office of Rare Diseases Research, NCATS, NIH

Rachelle Jacques, CEO, Akari Therapeutics

Bill Mezzanotte, Global, Head, R&D & CMO, CSL

Gilmore O’Neill, CEO, Editas Medicine

Moderator: Martin MackayExecutive Chair & Co-Founder, Rallybio

2:30 pm

NETWORKING BREAK

3:00 pm

GETTING TO REGULATORY APPROVAL

Peter Hutt, General Counsel (former), FDA

Thomas Lonngren, Chair, Egetis Therapeutics AB; Executive Director (former), EMA

Stef Schutte, EVP, Head, Regulatory Affairs, Astellas

Moderator: Bill Lundberg, CEO, Merus

3:30 pm

FIRESIDE CHAT

Steve Elledge, Professor, Genetics, Harvard Medical School

Bill Kaelin, Sidney Farber Professor of Medicine, Dana-Farber Cancer Institute

Tim Springer, Latham Family Professor, Harvard Medical School

Moderator: Christoph Westphal, General Partner, Longwood Fund

4:00 pm

CROSS-CULTURAL COLLABORATION

Hank Safferstein, CEO, Generian

Ramona Sequeira, President, Global Portfolio Division, Takeda

Matt Stober, CEO, Abzena

Dan Wolf, SVP, Strategy & BD, Baxter

Moderator: Joe Payne, CEO, Arcturus Therapeutics

4:30 pm

DEVELOPING THE SYNDICATE

Christine BrennanManaging Director, Vertex Ventures

Ansbert Gadicke, Managing Director, MPM Capital

Alaa Halawa, Executive Director, Mubadala

Omar Khalil, Partner, Sante Ventures

Moderator: David Steinberg, General Partner, Longwood Fund

5:00 pm

COCKTAIL RECEPTION

Day 2

7:00 am

REGISTRATION & NETWORKING BREAKFAST

7:30 am

LONGWOOD FUND INTRODUCTION

David Steinberg, General Partner, Longwood Fund

8:00 am

R&D COLLABORATION

Brian Fenton, CEO, Photys

Iris Grossman, Chief Therapeutics Officer, Eleven Therapeutics

Roger Palframan, Head, Research, US, UCB

Uli Stilz, Head, Bio Innovation Hub, Novo Nordisk

Matt Tremblay, CEO, Blackbird Labs

Moderator: Errik Anderson, CEO, Alloy Therapeutics

8:30 am

INNOVATIVE COMMERCIAL MODELS

Arpa Garay, CCO, Moderna

Eddie Martucci, CEO, Akili Interactive

Mike Shine, SVP, Commercial, Ocugen

Jason Tardio, Chief Operating Officer, Ovid

Moderator: Brian Fox, President, Commercial, Klick

9:00 am

AGE OF -OMICS

Fabrice Chouraqui, CEO, Cellarity

George Church, Professor, Genetics, Harvard Medical School

Elliot EhrichCMO, Life Mine Therapeutics

Li Peng, CSO, Palleon Pharmaceuticals

Moderator: Saul Kato, CEO, Herophilus

9:30 am

FIRESIDE CHAT

Rochelle Walensky, Director, CDC (2021-2023)

Moderator: Christoph Westphal, General Partner, Longwood Fund

9:50 am

NETWORKING BREAK 

10:20 am

MANAGING THE RUNWAY

Carl Firth, CEO, ASLAN Pharmaceuticals

Luba Greenwood, CEO, Kojin Therapeutics

Nenad Grmusa, CEO, DEM Biopharma

Axel Hoos, CEO, Scorpion Therapeutics

Moderator: Brian McVeigh, Chairman, CEO and Co-Founder, Code Biotherapeutics

10:50 am

KEEPING THE PATIENT AT THE CENTER

Brian Alexander, CEO, Foundation Medicine

Al Gianchetti, CEO, XyloCor

Laurie Glimcher, CEO, Dana-Farber Cancer Institute

Ivana Magovcevic-LiebischCEO, Vigil Neuroscience

Moderator: Maria Whitman, Managing Partner, Global Commercialization Strategy, ZS Associates

11:20 am

TARGETED M&A

Andrew Davis, CBO, Ironwood Pharmaceuticals

Mark McKenna, CEO, Prometheus

Matt Roden, CEO, Aktis Oncology

Moderator: Chris Roop, Co-Head, M&A Group, Jefferies

11:50 am

ADVANCING RESEARCH INTO THE CLINIC

Jennifer Michaelson, CSO, Cullinan Oncology

Joel Schneider, CEO, Carbon Biosciences

Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute

Moderator: Catherine Pagliarulo, VP, Science & Technology, Alexandria Real Estate Equities

12:20 pm

NETWORKING LUNCHEON

1:00 pm

FOUNDATIONAL PARTNERING STRATEGY

Debbie Drane, SVP Global Commercial Development & TA Strategy, CSL Behring

Trevor MartinCEO, Mammoth Biosciences

Chad Robins, CEO, Adaptive Biotech

Heather Wasserman, COO & CBO, Remix Therapeutics

Moderator: Jason Cole, CEO, SalioGen Therapeutics

1:30 pm

CURRENT STATE OF TALENT RECRUITMENT & RETENTION

Amira Barkal, Chief Development Officer, Pheast

Paul Froisland​, SVP and Head of Human Resources, Senda Biosciences

Phil VickersCEO, Solu Therapeutics

Krishnan Viswanadhan, President & COO, Be Bio

Moderator: Cissy YoungPartner, Catalyst Advisors

2:00 pm

FIRESIDE CHAT

Dave Reese, EVP, R&D, Amgen

Priya Singhal, EVP & Head, Development & Interim Head of Research, Biogen

Moderator: Colin Hill, CEO, Aitia

2:20 pm

THE NEXT WAVE OF TARGETED THERAPIES

Kyle Holen, SVP, Head, Development, Therapeutics & Oncology, Moderna

Matt Henn, CSO, Seres Therapeutics

Gavin MacBeath, CEO, TScan

Moderator: Chen Schor, CEO, Adicet Bio

2:50 pm

NETWORKING BREAK

3:25 pm

EXTERNAL INNOVATION

Kathy Fernando, SVP, Head, Pfizer Ignte & Pfizer CentreOne

Michael Flaschen, SVP, Head, Global External Innovation, Daiichi Sankyo

Ariel Katz, CEO, H1

Ernesto Martinez, Head, Corporate Development & Innovation, MassChallenge

Shanshan Xu, Global Head, External Innovation, BioNTech

Moderator: Michal Preminger, Head, Innovation, E. North America, Johnson & Johnson

4:00 pm

PIPELINE PRIORITIZATION

Lori Grosso, Global Clinical Development Lead, Tevogen

Johan Luthman, Head, R&D, Lundbeck

Rick Morgan, CSO, Be Bio

Simona Skerjanec, SVP & Global Therapeutic Area Head, Neuroscience & Rare Diseases, Roche

Moderator: Lisa Ricciardi, CEO, Cognition Therapeutics

4:30 pm

INVESTMENT OUTLOOK

Ness Bermingham, Operating Partner, Khosla Ventures

Michelle Detwiler, Managing Partner, Biospring

Mike Ehlers, CSO & Venture Partner, Apple Tree Partners

Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund

5:00 pm

COCKTAIL RECEPTION

Supporters 

​To learn more about getting involved contact sg@longwoodfund.com

logo-dark (1).png
MYRA EB SYSTEMS.png
bottom of page